Researchers have developed a new fluorescent dye that detects ovarian cancer tumors during surgery with 90.20% accuracy, compared to 78.75% for the current standard dye. According to Gram Research analysis, this new probe uses deeper-penetrating light and can reliably identify tumors smaller than 3 millimeters that surgeons cannot see with their eyes alone. The dye works by targeting proteins abundant on cancer cells, allowing surgeons to remove more cancer tissue during operations. While these results come from animal studies and human trials are needed, this advancement could improve surgical outcomes for ovarian cancer patients by enabling more complete tumor removal.

Researchers have developed a new fluorescent dye that helps surgeons see ovarian cancer tumors during surgery, even tiny ones hidden from the naked eye. According to Gram Research analysis, this new dye works better than the current standard tool used in operating rooms. The dye uses a special light wavelength that penetrates deeper into body tissue, allowing surgeons to spot and remove more cancer cells. In animal studies, the new probe found 90% of tumors compared to 79% with the current standard, and could even detect tumors smaller than a grain of rice. This breakthrough could help surgeons remove more cancer during operations, potentially improving outcomes for ovarian cancer patients.

Key Statistics

A 2026 research article published in Science Advances found that a new near-infrared II fluorescent dye detected 90.20% of ovarian cancer tumors in mice, compared to 78.75% detection with OTL38, the current clinical standard dye used in operating rooms.

The new folate receptor-targeted imaging probe reliably identified ovarian cancer lesions measuring 3 millimeters or smaller in animal models, tumors that are typically invisible to the surgeon’s naked eye during surgery.

The improved tumor detection with the new dye stems from its ability to penetrate deeper into tissue using near-infrared II light wavelengths (1000 to 3000 nanometers) compared to the near-infrared I range (700 to 1000 nanometers) used by current surgical probes.

The Quick Take

  • What they studied: Whether a new glowing dye can help surgeons see ovarian cancer tumors better during surgery compared to the dye currently used in hospitals
  • Who participated: Laboratory mice with ovarian cancer that had spread to the abdomen, mimicking how the disease spreads in human patients
  • Key finding: The new dye found 90.20% of tumors versus 78.75% with the standard dye, and could detect tumors as small as 3 millimeters or smaller
  • What it means for you: If approved for human use, this dye could help surgeons remove more cancer during surgery, potentially improving survival rates. However, this is still early-stage research in animals, and human trials would be needed before it becomes available in hospitals

The Research Details

Scientists created a new fluorescent dye designed to stick to ovarian cancer cells. The dye uses a special type of light called near-infrared II, which penetrates deeper into body tissue than the light used by current surgical dyes. They attached the dye to a protein that naturally binds to cancer cells, helping it find and highlight tumors. The researchers tested this new dye in mice with ovarian cancer that had spread throughout the abdomen, comparing how well it worked compared to OTL38, the dye currently used in operating rooms. They measured how many tumors each dye could detect and how small the tumors could be while still being visible.

Current surgical dyes have limitations: they don’t penetrate deep enough into tissue and don’t provide clear enough images. This means surgeons may miss small cancer spots during surgery. A better dye could help surgeons remove all visible cancer, which is the main goal of ovarian cancer surgery. Complete removal of cancer during the first surgery is linked to better long-term survival rates for patients

This study was published in Science Advances, a highly respected scientific journal. The research used animal models that closely mimic how ovarian cancer spreads in humans. However, animal studies don’t always translate directly to humans, so human clinical trials would be necessary before this dye could be used in hospitals. The study focused on the dye’s technical performance rather than testing it in actual surgical procedures

What the Results Show

The new dye outperformed the current standard dye in detecting ovarian cancer tumors. In the animal studies, the new probe successfully identified 90.20% of tumors, compared to 78.75% detection with OTL38, the current clinical standard. This represents an 11.45 percentage point improvement in tumor detection. The new dye was particularly effective at finding very small tumors, reliably detecting lesions that measured 3 millimeters or smaller. These tiny tumors are often invisible to the surgeon’s naked eye and are frequently missed during surgery, leaving cancer behind that can regrow later. The improved detection came from the dye’s ability to penetrate deeper into tissue and stay in the bloodstream longer, allowing it to accumulate more effectively in cancer cells

The new dye’s improved performance appears to come from its chemical structure, which allows it to bind to albumin, a protein in the blood. This binding keeps the dye circulating longer in the body, giving it more time to find and accumulate in cancer cells. The dye specifically targets folate receptors, proteins that are abundant on ovarian cancer cells but rare on healthy cells, making it selective for cancer tissue. The deeper tissue penetration of the near-infrared II light wavelength used by the new dye means surgeons could potentially see tumors that are buried deeper in tissue layers

OTL38, the current standard surgical dye for ovarian cancer, has been used in hospitals for several years and has improved surgical outcomes. However, it operates in the near-infrared I range, which doesn’t penetrate as deeply into tissue. This new research builds on the success of OTL38 by addressing its main limitations. The improvement in detection sensitivity from 78.75% to 90.20% represents meaningful progress in surgical imaging technology. Other research groups have explored near-infrared II imaging for cancer surgery, but this study demonstrates superior performance specifically for ovarian cancer detection

This research was conducted only in laboratory mice, not in human patients. Mouse tumors may behave differently than human tumors, and the mouse abdomen is much smaller than a human abdomen, which could affect how the dye performs. The study measured the dye’s ability to detect tumors in controlled laboratory conditions, not during actual surgical procedures where factors like bleeding, tissue movement, and surgeon experience could affect results. The researchers did not test the dye’s safety in living animals or measure potential side effects. No information was provided about the dye’s cost or how difficult it would be to manufacture for widespread hospital use. Human clinical trials would be necessary to confirm these results apply to ovarian cancer patients

The Bottom Line

This research is promising but still in early stages. It should not change current ovarian cancer treatment practices. Patients and doctors should continue using current standard surgical approaches. However, this work suggests that improved surgical imaging tools may become available in the future. If this dye advances to human trials and receives regulatory approval, it could become a valuable tool for surgeons. Confidence level: Low to moderate for near-term clinical application, as human trials have not yet been conducted

Ovarian cancer patients and their doctors should be aware of this development as a potential future improvement in surgical care. Gynecologic surgeons and cancer researchers should follow this work as it advances. Women at high risk for ovarian cancer may benefit from understanding emerging surgical technologies. This research is not immediately relevant to patients currently undergoing treatment, as the dye is not yet available for human use

If this dye moves forward to human clinical trials, it typically takes 3 to 7 years for new surgical imaging agents to receive regulatory approval and become available in hospitals. Even after approval, it may take additional time for hospitals to adopt the technology and train surgeons to use it. Patients should not expect this dye to be available for their surgery in the near term, but it represents progress toward better surgical tools

Frequently Asked Questions

How does the new ovarian cancer imaging dye work differently than current surgical dyes?

The new dye uses deeper-penetrating light and stays in the bloodstream longer, allowing it to accumulate better in cancer cells. It detected 90.20% of tumors versus 78.75% with current dyes, and can find tumors smaller than 3 millimeters that surgeons cannot see with their eyes

When will this new imaging dye be available for ovarian cancer surgery?

This research is still in animal testing stages. If it advances to human clinical trials, regulatory approval typically takes 3 to 7 years. Patients should not expect this dye to be available for surgery in the near term, but it represents progress toward better surgical tools

Can this new dye improve survival rates for ovarian cancer patients?

Potentially, yes. Removing all visible cancer during surgery is linked to better survival rates. By helping surgeons find and remove more cancer, this dye could improve outcomes. However, human trials are needed to confirm this benefit in actual patients

Is this new imaging technology safe for human use?

Safety has not yet been tested in humans. The research only measured how well the dye detects tumors in mice. Human clinical trials would need to evaluate safety, side effects, and how the dye performs in actual patients before hospital use

What makes this dye better at finding small ovarian cancer tumors?

The dye uses near-infrared II light that penetrates deeper into tissue than current dyes. It also binds to a blood protein that keeps it circulating longer, giving it more time to find cancer cells and accumulate in tumors

Want to Apply This Research?

  • Users with ovarian cancer history could track surgical follow-up appointments and imaging test results to monitor for recurrence, noting dates and outcomes of CT scans, ultrasounds, or other imaging studies
  • Set reminders for recommended cancer surveillance appointments and imaging screenings. Users could log discussions with their oncology team about emerging surgical technologies and new treatment options to stay informed about advances in their care
  • Maintain a timeline of all cancer-related imaging and surgical procedures. Track any new symptoms or concerns between appointments. Document conversations with healthcare providers about new technologies that may become available, creating a record to discuss at future appointments

This research describes an experimental imaging dye that has only been tested in laboratory animals. It is not approved for human use and is not currently available in hospitals. This article is for educational purposes only and should not be interpreted as medical advice. Ovarian cancer patients should continue following their doctor’s recommendations for treatment and surveillance. Any decisions about cancer treatment should be made in consultation with qualified oncologists and surgeons. This research represents early-stage scientific work that may or may not lead to approved clinical applications. Always consult with your healthcare provider before making any changes to your cancer care plan.

This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.

Source: A folate receptor-targeted NIR-II probe improves intraoperative imaging and surgery of metastatic ovarian cancer. , Science advances (2026). PubMed 42826211 | DOI
Topics
ovarian cancer surgery fluorescent imaging dye surgical imaging technology cancer detection near-infrared imaging tumor visualization gynecologic cancer precision surgery